Human papillomavirus vaccine update

被引：11

作者：

Ames A. ^{[1
]}

Gravitt P. ^{[1
]}

机构：

[1] Department of Epidemiology and Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231

来源：

Current Infectious Disease Reports | 2007年 / 9卷 / 2期

关键词：

Cervical Cancer; Cervical Intraepithelial Neoplasia; Cervical Cancer Prevention; Quadrivalent Vaccine; Vulvar Intraepithelial Neoplasia;

D O I：

10.1007/s11908-007-0011-6

中图分类号：

学科分类号：

摘要：

With the approval of Gardasil® (Merck and Co., Inc., Whitehouse Station, NJ) in June of 2006 and the pending approval of Cervarix® (GlaxoSmithKline, London, UK), two prophylactic human papilomavirus (HPV) vaccines will be available for clinical use. Randomized controlled trials have shown that both vaccines are safe and highly effective in preventing persistent infection and lesions caused by HPV 16 and 18 - the types responsible for 70% of cervical cancers worldwide. Determining an effective vaccination strategy is now the most pressing issue facing clinicians, parents, public health officials, and policy makers. We discuss the appropriate age of vaccination, vaccine acceptance, implementation strategies in low resource settings, and the future of screening. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：151 / 158

页数：7

共 34 条

[1] Parkin D.M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002, CA Cancer J Clin, 55, pp. 74-108, (2005)
[2] Denny L., Quinn M., Sankaranarayanan R., Chapter 8: Screening for cervical cancer in developing countries, Vaccine, 24, SUPPL. 3, (2006)
[3] Gravitt P., Shah K., A virus-based vaccine may prevent cervical cancer, Curr Infect Dis Rep, 7, pp. 125-131, (2005)
[4] Koutsky L.A., Ault K.A., Wheeler C.M., Et al., A controlled trial of a human papillomavirus type 16 vaccine, N Engl J Med, 347, pp. 1645-1651, (2002)
[5] Koutsky L.A., Harper D.M., Chapter 13: Current findings from prophylactic HPV vaccine trials, Vaccine, 24, SUPPL. 3, (2006)
[6] (2006)
[7] Hildesheim A., Herrero R., Effect of a HPV 16/18 vaccine on resolution of infections in women with pre-existing HPV, 23rd International Papillomavirus Conference & Clinical Workshop, (2006)
[8] Stanley M., Lowy D.R., Frazer I., Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms, Vaccine, 24, SUPPL. 3, (2006)
[9] Harper D.M., Franco E.L., Wheeler C.M., Et al., Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial, Lancet, 367, pp. 1247-1255, (2006)
[10] Villa L.L., Ault K.A., Giuliano A.R., Et al., Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18, Vaccine, 24, pp. 5571-5583, (2006)

← 1 2 3 4 →